TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01523002
Drug: Metoprolol and pyronaridine-artesunate
Normalized name: Artesunate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period.
Study: NCT01523002
Drug: pyronaridine-artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period.
Study: NCT03420521
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg IV over 60 minutes Q2W
Study: NCT03420521
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg/kg IV over 30 minutes Q6W
Study: NCT01119664
Drug: SCH 721015
Normalized name: SCH-209702/SCH-721015
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727597
Drug: Efavirenz 600mg
Normalized name: EFAVIRENZ 600MG TAB
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
Study: NCT00727597
Drug: Boosted Lexiva
Normalized name: Lexiva
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
Study: NCT00001797
Drug: Recombinant human interleukin-10
Normalized name: Recombinant human interleukin-10 fusion protein
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03590054
Drug: Abexinostat
Normalized name: Abexinostat
DrugBank: Abexinostat (DB12565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
Study: NCT01510782
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of escalating doses
Study: NCT01510782
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of escalating doses
Study: NCT03953612
Drug: Pregnenolone (PREG)
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of PREG (300 or 500 mg/day)
Study: NCT01049646
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Study: NCT01049646
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Study: NCT02852551
Drug: PAT-1251
Normalized name: PAT-1251
DrugBank: PAT-1251 (DB16735)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01593046
Drug: TMC278 LA 600mg intramuscular injection
Normalized name: guaifenesin 600 MG [Humigen LA]
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg Loading dose given at month 4
Study: NCT01958138
Drug: comparison of group-I (low dose propofol with isoflurane)
Normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
Study: NCT03778073
Drug: Cosibelimab
Normalized name: Cosibelimab
DrugBank: Cosibelimab (DB15770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
Study: NCT03778073
Drug: Cosibelimab + Ublituximab + Bendamustine combination
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Study: NCT03778073
Drug: Cosibelimab + Ublituximab + Bendamustine combination
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Study: NCT04273191
Drug: Brexanolone
Normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brexanolone will be initiated and administered per the USPI and the associated REMS.
Study: NCT02371473
Drug: Acetazolamide-placebo
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
Study: NCT02371473
Drug: Placebo-acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
Study: NCT01339754
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks
Study: NCT01339754
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
Study: NCT01519063
Drug: Naltrexone and memantine first
Normalized name: donepezil and memantine
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 50mg memantine 20mg
Study: NCT00002574
Drug: omacetaxine mepesuccinate
Normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01519063
Drug: Naltrexone and Placebo first
Normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 50 mg Placebo
Study: NCT03110198
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
Study: NCT03110198
Drug: Mesalazine with hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
Study: NCT05322057
Drug: Darvadstrocel
Normalized name: darvadstrocel
DrugBank: Darvadstrocel (DB16581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
Study: NCT02568124
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04363437
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
Study: NCT03030911
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Study: NCT03030911
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Study: NCT00740883
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 months of warfarin therapy, once daily
Study: NCT00740883
Drug: placebo of warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 months of placebo of warfarin therapy, once daily
Study: NCT02193256
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated over 1 week to a maximum dose of 2mg/day
Study: NCT02193256
Drug: Prazosin
Normalized name: Prazosin
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated over 3 weeks to a maximum dose of 8mg/day
Study: NCT02172092
Drug: SodiumChloride
Normalized name: Dextrose 2.5% and 0.45% SodiumChloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of SodiumChloride, blood samples to calculate extracellular volume.
Study: NCT00330525
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00288730
Drug: nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01074944
Drug: Eliglustat tartrate
Normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Capsule in 50 mg or 100 mg dosages
Study: NCT00703872
Drug: Oral HDV-Interferon + ribavarin
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naive pateints
Study: NCT00703872
Drug: Injectable HDV-Interferon + ribavarin
Normalized name: interferon gamma-1b Injection
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders
Study: NCT02442180
Drug: G-CSF (Filgrastim injection)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
Study: NCT02290444
Drug: Adrenocorticotropic Hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
Study: NCT06486870
Drug: Gonadotropin
Normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
Study: NCT00713648
Drug: catridecacog
Normalized name: Catridecacog
DrugBank: Catridecacog (DB09310)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 35 IU/kg body weight, i.v. administration, once every 4 weeks
Study: NCT04154956
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
Study: NCT00223860
Drug: Human chorionic gonadotropin (hCG)
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00223860
Drug: Luteinizing hormone releasing hormone (LHRH)
Normalized name: Luteinizing hormone
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00243724
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01564550
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
Study: NCT01564550
Drug: insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
Study: NCT06486870
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
Study: NCT04004611
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV and SC
Study: NCT03229954
Drug: Ferrous sulfate(Feroba-YOU) per oral
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
Study: NCT02017015
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
Study: NCT02017015
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
Study: NCT01738295
Drug: Donepezil administration
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03659929
Drug: Amphetamine Sulfate
Normalized name: amphetamine sulfate
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active experimental AR19
Study: NCT03310749
Drug: Gemigliptin
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Study: NCT03310749
Drug: Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
Study: NCT03310749
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
Study: NCT01185197
Drug: Myfortic plus low-dose steroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
Study: NCT01286753
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg orally twice daily.
Study: NCT05646459
Drug: cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
Study: NCT03278626
Drug: Nivolimumab+Carboplatin/paclitaxel+Radiation
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
Study: NCT02428439
Drug: bupropion or lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
Study: NCT02879318
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02879318
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02879318
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02879318
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03126331
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more.
Study: NCT03126331
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
Study: NCT03472274
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg every 4 weeks x 3 cycles
Study: NCT03472274
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 75 mg every 4 weeks x 3 cycles
Study: NCT03472274
Drug: Cisplatin-based neoadjuvant chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1
Study: NCT01240148
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose, intradermal injection
Study: NCT04674839
Drug: MS-20
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fermented soymilk product
Study: NCT01522625
Drug: tenofovir disoproxil fumarate 300mg per day
Normalized name: tenofovir disoproxil fumarate 300 MG
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir disoproxil fumarate 300mg per day for 3 years
Study: NCT02263495
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
Study: NCT02263495
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)